During the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers published findings on the economic impacts of nonmedical switching; while 1 study found that switching to biosimilar infliximab brought down costs without sacrificing efficacy or safety, but another raised concerns about increases in overall healthcare utilization.
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers published findings on the economic impacts of nonmedical switching; while 1 study found that switching to biosimilar infliximab brought down costs without sacrificing efficacy or safety, but another raised concerns about increases in overall healthcare utilization.
In an efficacy and cost analysis of a switch from reference infliximab to CT-P13 (Inflectra, Remsima) in a single center in Lisbon, Portugal, a total of 60 patients who were stable on reference infliximab for the treatment of rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis were switched to the biosimilar in 2016.1
The researchers reported that, during their observation period (median, 261 days), disease activity across patient groups was largely stable. The disease worsened in 3 patients (5%) while 1 patient had a minor adverse event. These 4 patients discontinued treatment with the biosimilar (1 resumed treatment with the reference and the other 3 changed to a different drug).
The switch to the biosimilar in the remaining patients resulted in a 26.4% reduction in the cost of infliximab, say the authors.
In a separate study, however, researchers presented a systematic literature review on the costs associated with nonmedical switching to biosimilars that found that, in the few studies available on the topic, healthcare resource utilization increased after undertaking a nonmedical switch.2
The researchers, all of whom disclose interests in AbbVie, conducted their review by searching for English-language studies in PubMed and Embase over the past decade. They found only 3 studies that reported on costs associated with switching; a single-center, 2-cohort study found that switching was associated, versus remaining on an originator product, with higher inpatient readmission (80% versus 5%; P =.001) surgery rate (29% versus 0%; P =.02), and steroid use (60% versus 8%; P <.001).
Another single-center study reported more patient visits and phone consultations due to injection-site pain among patients who switched, and the third study, based on a national patient registry, found that outpatient visit days increased among those who switched versus those who did not (5.7 days versus 5.4 days; P <.001).
A comprehensive evaluation of the economic consequences of switching, write the authors, should incorporate not savings from lower prices of drugs, but also such factors as healthcare resource utilization in order to arrive at a more robust understanding of the economic impact of switching.
References
1. Valido A, Silva-Dinis J, Saavedra MJ, Bernardo N, Fonseca JE. Efficacy and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 in patients with inflammatory arthritis from a single center. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB1231. doi: 10.1136/annrheumdis-2018-eular.5844.
2. Liu Y, Garg V, Yang M, Wu EQ, Skup M. Economic impact of non-medical switching from originator biologics to biosimilars—a systematic literature review. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB1276. doi: 10.1136/annrheumdis-2018-eular.4975.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.